| Review of cefditoren, an advanced-generation, broad-spectrum oral cephalosporin. | |
| | |
MedLine Citation:
|
PMID: 11813929 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Cefditoren is an advanced-generation, broad-spectrum cephalosporin antibiotic approved for the treatment of acute bacterial exacerbation of chronic bronchitis (AECB), group A beta-hemolytic streptococcal pharyngotonsillitis, and uncomplicated skin/skin structure infections in adult and adolescent patients. OBJECTIVE: This article briefly reviews the chemistry, antimicrobial activity, pharmacokinetics, efficacy, and safety of cefditoren. METHODS: Literature was identified by a MEDLINE search (January 1985 to October 2001) of the medical literature, review of the English-language literature, reference lists within these articles, as well as data presented at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. RESULTS: Cefditoren has a broad spectrum of activity against many gram-negative and gram-positive aerobes, including Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. Cefditoren is stable to hydrolysis by many common beta-lactamases. Cefditoren is rapidly absorbed (time to peak plasma concentration, approximately 2-3 hours) from the gastrointestinal tract and is almost completely eliminated via renal clearance of unchanged drug. The terminal disposition half-life of the compound is approximately 0.8 to 1.3 hours. CONCLUSIONS: Cefditoren is effective in the management of AECB (in regimens of 400 mg twice daily for 10 days) and acute maxillary sinusitis, pharyngotonsillitis due to S pyogenes, and uncomplicated skin/skin structure infections (in regimens of 200 mg twice daily for 10 days). Cefditoren possesses broad activity against common pathogens of the respiratory tract and skin and is stable in the presence of numerous beta-lactamases. Its pharmacokinetic properties, in conjunction with in vitro susceptibility data, document the feasibility of twice-daily dosing. |
| | |
Authors:
|
D R Guay |
Related Documents
:
|
9163689 - Carcinogenesis induced by uva (365-nm) radiation: the dose-time dependence of tumor for... 9758679 - Enhanced skin permeation of sex hormones with novel topical spray vehicles. 18713079 - In vitro dermal absorption and metabolism of d&c red no. 17 in human and porcine skin. 15593189 - Efficacy and tolerability of a selective alpha(2c)-adrenergic receptor blocker in recov... 12662909 - Skin irritation, basal epithelial cell proliferation, and carcinogenicity evaluations o... 3820339 - Biochemical and morphological studies on the percutaneous uptake of [14c] ethylenediami... 6679519 - Tolerability and serum levels of benoxaprofen in healthy volunteers. 1159089 - Comparison of agents producing a neutrophilic leukocytosis in man. hydrocortisone, pred... 19025819 - Low-dose corticosteroids and avascular necrosis of the hip and knee. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Clinical therapeutics Volume: 23 ISSN: 0149-2918 ISO Abbreviation: Clin Ther Publication Date: 2001 Dec |
Date Detail:
|
Created Date: 2002-01-29 Completed Date: 2002-07-12 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7706726 Medline TA: Clin Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 1924-37; discussion 1923 Citation Subset: IM |
Affiliation:
|
Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota, and PartneringCare Senior Services, HealthPartners, Minneapolis 55455, USA. guayx001@tc.umn.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adolescent Adult Area Under Curve Bacterial Infections / drug therapy* Cephalosporins* / chemistry, pharmacokinetics, therapeutic use Chromatography, High Pressure Liquid Half-Life Humans Intestinal Absorption Microbial Sensitivity Tests Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Cephalosporins; 104145-95-1/cefditoren |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Use of terbutaline in the treatment of complete heart block in the fetus.
Next Document: Insulin glargine.